0001209191-22-060966.txt : 20221213
0001209191-22-060966.hdr.sgml : 20221213
20221213170420
ACCESSION NUMBER: 0001209191-22-060966
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221209
FILED AS OF DATE: 20221213
DATE AS OF CHANGE: 20221213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brumm Joshua T
CENTRAL INDEX KEY: 0001528826
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 221460350
MAIL ADDRESS:
STREET 1: ZELTIQ AESTHETICS INC.
STREET 2: 4698 WILLOW ROAD SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-09
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001528826
Brumm Joshua T
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD
WALTHAM
MA
02451
1
1
0
0
See Remarks
Common Stock
2022-12-09
4
A
0
144000
0.00
A
333123
D
Common Stock
2022-12-12
4
S
0
3322
10.87
D
329801
D
Stock Option (right to buy)
10.72
2022-12-09
4
A
0
222000
0.00
A
2032-12-08
Common Stock
222000
222000
D
Consists of shares of Common Stock issuable under 144,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.
Includes 293,544 unvested RSUs.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
Includes 286,157 unvested RSUs.
This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.
Chief Executive Officer and President
/s/ Richard Scalzo, Attorney-in-Fact
2022-12-13